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Poly(ADP-ribose)polymerase (PARP) overactivation induces cell 
death called parthanatos via production of large swells of PAR. 
Parthanatos is apparent in debilitating diseases such as stroke and 
Parkinson’s disease. PAR is complex polymer of ADP-ribose with different 
sizes and branching structures. Complex PAR is more toxic as compared 
to shorter length PAR. The role of different PAR species play in disease 
complexity and progression is still unknown. Moreover, the tools 
currently available are not sensitive enough to detect the differences in 
PAR species. While the current antibodies available are capable of 
detecting PAR for immunoblot analysis and immunohistochemistry 
analysis, the detection threshold is high and specificity for varying PAR 
structures is low. Here, we generated a panel of recombinant antibodies 
using phage display HuCal technology to effectively detect PAR species in 
different disease models. PAR induces cell death via translocation of AIF 
to the nucleus. To further understand how different species of PAR 
regulate the nuclear translocation of AIF, we generated a PAR-binding 
mutant AIF transgenic knock-in mouse. Induction of stroke via middle 
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Parthanatos: PARP-1 dependent cell death 
Parthanatos is a key cell death mechanism involved in various diseases 
including ischemic injury and excitotoxicity. It involves poly(adenosine 
diphosphate-ribose) polymerase (PARP), which has been documented to play a 
role in both DNA repair and in cell death.1 Under conditions of oxidative stress 
from reactive oxygen species (ROS), or cytotoxicity, cells will exhibit DNA 
damage. The role of the PARP family proteins, which are involved in base 
excision repair, allow for the repair of DNA damage upon activation of cell cycle 
checkpoints.2 PARP-1 is a 116kDa protein containing three major domains: 
DNA binding domain (with nuclear localization sequence), catalytic domain 
(55kDa), and automodification domain (16kDa) that are responsible for 
harboring the NAD-bidning domain and PAR synthesizing domain.3,4  The 
amino acid sequence is also highly conserved between the human and 
mouse, with up to 92% homology.5 
Under the condition of DNA damage, PARP-1 utilizes nicotinamide 
adenine dinucleotide (NAD+) to generate nicotinamide and ADP-ribose, 
where subsequent ADP-ribose are linked in a long simple and complex 
branched chain of PAR polymers. The PAR polymer acts as a recruiter of 
other proteins, such as XRCCI and histones to recruit DNA polymerase 
and DNA ligase III to repair the single or double stranded break. In sum 
PARP-1 plays a role in maintaining cellular homeostasis and genomic 




 PARP-1 overactivation causes parthanatos, which is a dominant 
form of cell death in stroke, glutamate excitotoxicity, and other 
inflammatory processes.7 Release of apoptosis inducing factor (AIF) from 
the mitochondrial membrane and nuclear translocation induces 
chromatin condensation and large-scale DNA fragmentation. This activity 
is a prominent feature in Parthanatos. Unlike in apoptosis, PARP-1-
mediated cell death, parthanatos, does not result in formation of 
apoptotic bodies. Furthermore, parthanatos is caspase-independent, as 
caspase-inhibitors fail to rescue cells undergoing parthantos.8 It is also 
distinct from necrosis, in that it does not induce cell swelling. Studies 
have shown that the pathway is also caspase-independent, and hence 
parthanatos is an alternative form of programmed cell death. 
Although energy depletion plays a factor in parthanatos, studies 
indicate that energy depletion alone is insufficient in causing 
parthanatos. In fact, primary cell cultures studies show that energy 
depletion was not the primary factor.9 
Under conditions of parthanatos, PARP-1 is responsible for the 
majority of the PAR polymer generation, while maintaining a low basal 
level of PAR in normal conditions. The PAR polymer induces cell death in 
a manner dependent on its length, branching structure, and complexity. 
10When direct delivery of PAR polymer was administered to primary 
neuron cultures and HeLa cells, it was found that complex PAR polymers 




concentration of the 60-mer PAR polymer is increased, the cells exhibit a 
dose-dependent toxicity, comparable to NMDA excitotoxicity or MNNG-
induced cell death.10 Previous studies have also administered equal levels 
of poly-adenine, which has equivalent negative charge to the PAR 
polymer. These did not show the same toxic effect as PAR polymer.10 
Poly(ADP-ribosyl)ated proteins might also contribute to PARP-1-
mediated cell death.11 PARP substrates include many cytoplasmic and 
nuclear proteins, which are covalently modified by PAR.12 Modification by 
Poly(ADP-ribosyl)ation alters the charge distribution and adds bulky 
structures to target proteins, inhibiting physiological  protein function. 
Severe poly(ADP-ribosyl)ation of key cellular proteins might trigger 
downstream cellular death. Additionally, PAR polymers might directly be 
involved in cell-death signaling. The binding of cellular proteins to PAR 
polymer through a predicted consensus motif (composing of hydrophobic 
and basic amino-acid residues) could lead to additional signaling routes. 
Therefore, PAR polymer is an important signaling molecule that might be 
an attractive therapeutic target through the interference of the 
downstream signaling of PAR polymer. 
There is strong evidence of parthanatos involvement in Parkinson’s 
disease (PD). In PD patients, neurons show marked nuclear translocation 
of AIF.13 Additionally, MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) has been used as a common model for PD cell death. 




phenylpyridinium) by monoamine oxidase,15 which inhibits 
mitochondrial complex I activity. The disruption of the mitochondrial 
function leads to energetic failure and thereby increasing glutamate 
accumulation and hyperstimulation of glutamate receptor.16 This leads 
to downstream NO-activation and activation of PARP-1 following DNA 
damage.17 In the MPTP model, aminoacyl-tRNA synthetase complex 
interacting multifunctional protein-2 (AIMP2), 18which is a substrate of 
the E3 ubiquitin ligase PARKIN, accumulation has been identified. In in 
vitro and in vivo studies, AIMP2 accumulation resulted in PARP-1 
activation, providing another pathway for parthanatos other than DNA 
damage. 
Ischemic injury has also been linked with PARP-1 activation 
through the release of excitatory neurotransmitter glutamate. The over 
activation of three subtypes of glutamate receptors: N-methyl-D-
aspartate (NMDA), AMPA and kainate receptors, leads to massive calcium 
influx, resulting in the generation of nitric oxide (NO) and reactive oxygen 
species (ROS). Superoxide can combine with NO forming peroxynitrite 
(ONOO-). These ROS and radicals induce chromosomal DNA breaks, 
leading to the PARP-1 activation described previously. 
Current tools to detect PAR species are ineffective in detecting 
various types of PAR. The commercial PAR antibody 10H (Trevigen) has 
weak specificity with PAR and shows weak bands in western blot 




immune-precipitate significantly. It is still unknown the role of shorter 
length and structure PAR plays in parthanatos. While it is known that 
the addition of 60-mer PAR induces cell death, it is unclear the role of 
branching plays in the different models of parthanatos. Hence, the 
generation of improved antibodies for PAR will allow for better future 
studies involving the parthanatos pathway. 
Apoptosis Inducing Factor (AIF) 
Apoptosis inducing factor is a flavoprotein crucial in parthanatos. 
It serves a dual function in the cell, with separate binding sites for PAR 
and DNA, which appear to have evolved separate binding properties. 
Under normal conditions, AIF acts as an NADH oxidase, important in the 
electron transport chain in the mitochondria, involving the assembly and 
stabilization of respiratory complex I. It also has a role as a promoter of 
cell death, as AIF gets released to the cytoplasm after PARP-1 activation 
and translocated to the nucleus to induce cell death via large scale DNA 
fragmentation and chromatin condensation.19 
 Precursor AIF synthesized from a nuclear gene is 67 kDa. The  two 
mitochondrial localization sequences (N-terminal pro domain) allow for 
import to the mitochondria. At the mitochondria, it is then proteolytically 
cleaved to the mature 62 kDa form, where it resides as an inner 
membrane anchored protein, whose N-terminus is exposed to the 




space.20 There are two pools of AIF in the mitochondria, with 80% 
residing in the inner membrane and inner membrane space, where it is 
protected from direct PAR activity. The remaining 20% of mitochondrial 
AIF resides on the outer mitochondrial membrane, where it is susceptible 
to PAR binding and subsequent release in parthanatos.22 The three 
structural domains of mature AIF include a FAD-binding domain, a 
NADH-binding domain, and a C-terminal domain.21,22 The reduced form 
of AIF tends to form a dimer, suggesting that there may be a balance 
between the dimeric and monomeric forms in regulating AIF redox and 
apoptosis-inducing behaviors.23  
 The loss of AIF has been associated with growth impedance in 
development. In Drosophila melanogaster, knockout of AIF expression 
results in decreased embryonic cell death and preservation of 
differentiated neuronal cells, but exhibit growth arrest at the larval stage 
as well as mitochondrial respiratory dysfunction.24  
 The manner in which AIF affects respiratory machinery is yet to be 
fully understood. However, AIF redox has been indicated to be essential 
for cell survival. Harlequin (Hq) AIF-mutant mice, which have 80% 
reduced AIF expression, suggested that AIF has an important role in 
maintain cell physiology and long-term survival under basal conditions. 




translocates to the nucleus to initiate chromatin condensation and large 
scale DNA fragmentation.25  
PAR polymer can directly bind to AIF and facilitate its nuclear 
translocation and Parthanatos. AIF has been shown to bind directly to 
PAR, which is critical in its role to induce parthanatos.26 It is likely that 
PAR causes a conformational change in AIF upon binding, which lowers 
the affinity of it for the mitochondrial outer membrane. However, the 
exact mechanism that this occurs is still unclear. The Arg588, Lys589, and 
Arg592 in AIF are essential for the binding of PAR.17  
NMDA treatment of Hq cortical neurons transduced with WT-AIF 
were susceptible to NMDA excitotoxicity across 24 to 48 hour time points, 
in contrast to the effects seen in PAR-binding-mutant AIF-transduced 
(Pbm-AIF) Hq cortical neurons. It is PAR that disturbs the binding of AIF 
to the mitochondria, allowing its release and ultimate translocation to 
the nucleus. 
 To establish a stronger animal model of the Pbm-AIF, genetic 
knock-in mice for the Pbm-AIF were generated in BL6 mice for behavioral 
and stroke studies. Biocytogen was contracted to perform the 
mutagenesis via bacterial artificial chromosome (BAC). Briefly, gene 
sequences for each mutation site and probes were amplified by PCR and 
ligated into pCR-blunt vector and colonies were confirmed through 




fragments were ligated into pNLF or pDTA vectors and subsequently 
combined. This is then electroporated into BAC-containing competent 
cells. Once clones were tested to contain all the correct fragments, they 
were transformed into stbl3 and confirmed by sequencing following Maxi 
prep. This targeting vector was subsequently linearized by restriction 
enzyme digestion (AscI) and elctroporated into ES cells into 3.5 day 
embryos. Following transfection, selection process was done via geneticin.  
The resulting chimeras generated through this process were bred with 
BL6 mice for heterozygous F1 pups. 
The targeting vector in the F1 mice with the wild type and mutant 
AIF genes include a neo-cassette, which protects mammalian cells from 
the antibiotic neomycin, flanked by FRT sites. Removal of the neo-
cassette by breeding with FlpE mice will generate conditional knock-in 
mice via FLP—FRT recombination. (Figure 7) Further breeding of the 
floxed mice with proteamine-Cre mice results in Cre-Lox recombination 
for genetic Pbm-AIF knock in mice.  
 Transgenic mice with the Pbm-AIF knock in serves as a more 
robust model to evaluate PARP-1 activation compared to virally 
transduced Hq mice. In conjunction with previous data, it enables the 
more detailed study of the mechanism in which AIF release from the 
mitochondria induces cell death. Thus far, it has been difficult to 




function and therefore energy metabolism, complicating attempts to 
assess its role in cell death.27 With the newly generated transgenic mice 
that express the triple binding site mutants, AIF activity in the 
mitochondria can be effectively studied, as the release of AIF following 
PARP-1 activation is prevented. Further elucidation of the parthanatos 
signaling pathway will offer opportunities for the discovery of previously 
unidentified biological functions. Additionally, this might allow the 
discovery of potential drug compounds that might inhibit AIF binding 
with PAR to protect against parthanatos. It will also help identify drugs 
that promote AIF release in cancer cells as a chemotherapeutic agent. 
Human Combinatorial Antibody Library (HuCAL) Technology 
 The HuCAL technology presents an alternative method to the 
conventional methods of obtaining custom antibodies. Whereas the 
production of monoclonal antibodies requires immunizing a mouse, 
rabbit, or goat, and subsequently extracting the B cells from the spleen 
to recover the antibodies presented, HuCAL technology allows for faster 
production time. Through the use of library of complementarity 
determing regions (CDR), 6 light chain variable regions (VL) and 7 heavy 
chains (VH), it is possible to generate billions of antibodies in vitro. This is 
paired with a phage display that incorporates the antibody genes into 
bacteriophages that will present the antibody on the coating via a 




and genotype. A reductive cleavage of the disulfide bond will allow for the 
recovery of the antibodies following a screening, independent of the 
affinity to the antigen. AbD Serotec was provided with synthetic purified 
terminally-biotinylated PAR polymer. It was synthesized through 
reductive amination of pure PAR polymer (2-300mer).28 The antibody 
clones were selected for binding to only polymers and oligomers, and not 
the ADP-ribose monomer. 
 The HuCAL antibody generation process begins with the 
immobilization of the antigen (PAR), typically using the covalent coupling 
to magnetic beads. These are subsequently incubated with the HuCAL 
library where nonspecific antibodies are washed out and the specific 
antibody-phages will be eluted. E. coli cultures are then subjected to 
infection from the specific antibody-phages to generate an enriched 
antibody library for the subsequent round of phage screening. It is then 
that the DNA from these enriched antibody-phases are retrieved and 
subcloned into Fab expression vectors and plated into E. coli colonies to 
produce the Fab fragments. Following this are the colony picking, 
primary screening, where the colonies were grown in a 384-microtiter 
plate. Antibody expression is induced and collected after lysing the 
cultures. These cultures are screened by ELISA with the terminally 
labelled-PAR antigen. The positive hits from the primary screening will 
then be sequenced to identify the unique antibodies, which can be stored 




performed to select out PAR monomer binding antibodies. Finally, 
expression and purification through affinity chromatography was 
performed to obtain antibody clones. 
Results 
Characterization of the HuCAL antibodies 
 Enzyme-linked immunosorbent assay (ELISA) is commonly 
performed as a quality-control check to validate the specificity of the 
antibodies generated, as it is one of the most sensitive and reproducible 
assays. As such, the 19 antibody clones were tested against the biotin-
labeled PAR polymer, with increasing levels of the monomer ADP-ribose 
as inhibitors. (Figure 1) 
To characterize and evaluate the effectiveness of the HuCAL 
recombinant antibodies, western blot, immunostaining, and 
immunoprecipitation were performed on cell lysates.  Radiolabelled PAR 
samples were used to evaluate the specificity of the antibodies and 
determine the size of the PAR polymer recognized by the various HuCAL 
recombinant antibodies.    
MNNG treatment as a model 
MNNG is an alkylating agent, consisting of a nitrosourea structure, 
to induce PARP-1 activation.29 Under low concentrations of MNNG (0.5-




able to re-establish homeostasis.30 However, under high concentrations 
(100-500uM), DNA damage is extensive and the disproportionate 
activation of PARP-1 results in the downstream cell death from 
parthanatos. 
In time-dependent experiments, it was determined that PAR could 
be detected as early as 1 minute of treatment, but peaked between 10 to 
15 minutes of MNNG. This is consistent with the finding of early ROS 
production time points indicative of PARP-1 activation.31 
PARP inhibitors, notably 3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-
1(2H)-isoquinolinone (DPQ), have been used for treatment of ischemic 
stroke in animal models. More recently, potent PARP inhibitors have 
been shown to be effective in treating human cancers with DNA repair 
deficiency.32 BMN673 was identified as one of the most potent PARP1/2 
inhibitors with favorable metabolic stability and oral bioavailability, with 
effectiveness to be 20 to more than 200 fold compared to existing 
PARP1/2 inhibitors such as olaparib, rucaparib, and veliparb. This made 
the BMN 673 PARP inhibitor an ideal choice for assisting in the process 
of determining the specificity of the HuCAL recominbant antibodies.  
Western blot analysis 
 One of the primary uses for antibodies in the research setting is for 
the detection of proteins or antigens derived from cells after treatments. 




PARP-1 activation and PAR generation. As discussed previously, PAR 
production increases basal levels of PAR of up to 500 fold and ranges 
from 2 to 300mer in size. Hence, a western blot with a PAR antibody 
should indicate detection of oligomers and polymers in that range, 
thereby presenting a smear band. Previous PAR antibodies are able to 
detect PAR at narrower ranges and with reduced sensitivity. 
In the case of the HuCAL technology recombinant antibodies, all 
19 generated antibodies effectively detect poly ADP-ribosylated proteins 
to after 15 minutes MNNG treatment (Figure 2). Some are sensitive 
enough to detect basal levels (DMSO treated) of PAR, which indicates 
remarkable improvement to current commercial standards. In particular 
antibody clones 14, 17 19, 21, 25, 27, and 29 were highly specific to PAR 
and have superior signal-to-noise. Notably, the other antibodies, 13, 15, 
16, 18, 30, and 31, the PAR signal could still be detected even after 
inhibition with PARP1/2 inhibitor BMN 673, suggesting alternative PAR 
generation from PARP3 or non-specific immunoreactivity, particularly in 
the 70kD range.  
Immunohistochemistry 
Another use of the PAR antibodies that will allow better studies of 
parthanatos to be performed in the future is its ability to detect PAR in 
immunohistochemical samples. The ability to see PAR localization in the 




temporal and spatial aspects of the signaling pathway in different models. 
MNNG treatment is one model that allows for PAR visualization. 
Although PAR spreads rapidly from the nucleus to the cytoplasm, it was 
important to determine which of the antibody clones were capable of 
detecting which species of PAR. 
 Immunohistochemical analysis of the antibodies on HeLa cell 
samples and mouse cortical neurons indicate strong detection of PAR 
originating from the nucleus, and quickly spreading throughout the 
cytosol (Figure 3, 4). Notably, antibodies 14, 21, 25, 27, and 29 are the 
most specific to PAR following MNNG treatment, consistent with the 
immunoblot analysis. The DAPI nuclear stain allows for visualization of 
PAR production in the nucleus in a few of these antibody clones. It is 
likely that the PAR still in the nucleus are the larger polymer sizes, 
whereas those that spread quickly to the cytoplasm are the smaller 
oligomers. It is also noteworthy that antibody clones 19 and 27 showed 
detection within the nucleus as individual spots, perhaps indicative of 
PAR in the nucleolus. 
Immuno-precipitation 
Previous commercial antibodies do not effectively immune-
precipitate, and hence prevent researchers from isolating concentrated 
PAR samples. The antibodies generated here demonstrate robust ability 




cultures. The antibodies only have the Fab fragment, lacking the Fc 
region. It was important in determining the antibodies capacity for 
immune-precipitation. Immuno-precipitation via IgG binding magnetic 
beads indicated all antibodies to be effective in immune-precipitation 
(Antibody 19 probe). 
To further study the specificity of the PAR antibody to the various 
length PAR species, 32P-labelled PAR was prepared synthetically and 
immune-precipiated against the antibodies and visualized on a 
phosphorescent screen. Our results show that the panel of antibody 
clones offer a wide range of PAR size detection. It is apparent that 
antibodies 14 and 21 target low molecular weight PAR fragments, 
whereas antibodies 17, 18, 24, and 26 are more specific for high 
molecular weight PAR. Antibodies 19 and 29 were able to detect the 
whole range of PAR sizes. These results offer promising panel of 
antibodies that can be tailored for different disease models in PARP-1 
activation. 
Stroke model 
 PAR-binding mutant (Pbm) AIF knock-in mice were subjected to 
direct middle cerebral artery occlusion (dMCAo) as a model for stroke. 
Before strokes were performed, behavioral tests were performed. These 
included a cylinder test, spontaneous activity test, and a treadmill test. 




harvested 24 hours post reperfusion and stained with TTC. Preliminary 
results indicate reduced lesion volume for Pbm-AIF mice when compared 
to WT-AIF mice, indicative of some degree of protection. 
Discussion 
 Through the production of the 19 antibody clones through HuCAL 
recombinant technology, a panel of highly specific and effective PAR 
antibodies was characterized, allowing for future work to better 
characterize PARP-1 mediated cell death. Because the current tools 
available commercially for detection of PAR is limited and lacks the 
specificity for different PAR polymer sizes, the production of recombinant 
antibodies will provide a better method for future research studies to 
determine the relation of PAR structure and size with disease modalities. 
The characterization through immunoblot analysis indicated the robust 
strength of the antibodies to see the smear bands in PARP-1 activation, 
with even some demonstrating detection of basal PAR levels. 
Immunohistochemical analysis further supported the characterization 
process by identifying the localization of PAR using the antibody clones. 
Interestingly, the better antibodies for detection with lower noise were 
also the antibodies that detected smaller size PAR structures. Lastly, the 
immune-precipitation experiments were able to determine the size 




provide a strong foundation for future research in diseases involving 
PARP-1 cell death. 
 One of the models that the antibodies are useful in is in the genetic 
knock-in triple PAR-binding mutant AIF mice that were generated. These 
mice were subject to preliminary studies in behavioral and stroke models. 
Early results suggest promising protection capability of the mutant mice 
with no apparent side effects to mouse development and behavior. The 
PARP-binding mutant AIF allows the separation of AIF’s mitochondrial 
bionergetic functions and its cell death functions in the nucleus. In 
conjunction with the PAR recombinant antibodies, it would be interesting 
to determine the PAR sizes that AIF preferentially binds under PARP-1 
activation. Future work involving NMDA excitotoxicity through injection 
will be performed. In addition, cortical neurons cultured from timed 
pregnancy Pbm-AIF will be characterized via the XF analyzer to assess 













Cell Cultures and Extract 
HeLa S3 cells (ATCC) were grown in Dulbecco’s modified eagle’s 
medium (Invitrogen) with 10% Fetal bovine serum (Gibco). Mouse cortical 
neurons were cultured from gestational day 15 fetal mice CD1 mice 
(Jackson) as described previously (Dawson et al., 1991b, 1993b). Briefly, 
the dissected cortex cells were dissociated using Modified Eagle’s 
medium (Invitrogen), 20% horse serum, 25mM glucose, and 2mM L-
glutamine by trituration after 30 min digestion in trypsin/saline solution. 
To inhibit proliferation of glial cells and non-neuronal cells, cells were 
treated with 5-fluro-2-deoxyuridine on DIV4. They are maintained in the 
MEM with 10% horse serum, 25mM glucose, 2mM L-glutamine, until day 
14 when mature levels of nNOS are expressed. 
Cytotoxicity  
MNNG (100uM) was administered to cortical neuron cultures and 
HeLa cells for 15 minutes, with a washout at 15 minutes in culture 
medium and whole cell lysates were subsequently collected in RIPA lysis 
buffer.  BMN673 was administered to neuron cultures and HeLa cells 30 





32P-labeled PAR was synthesized by incubating PARP-1 with 32P-
labeled NAD+ for 2 minutes at 30°C and further incubated with 
nonlabelled and nonisotopic NAD+ for 28 min at 30°C.33 32P-labeled free 
PAR was then purified through a dihydroxyboronyl BioRex (DHBB) 
column as described.34 
Immunoblot analysis 
Immunoblots were performed from HeLa cell lysates after exposure 
to MNNG for 15 minutes. Whole cell lysates were boiled in 2 X Laemmli 
buffer for 10 minutes and analyzed on 8% SDS Page.  Following a wet-
transfer to nitrocellulose membrane and blocked for 1 hour at room 
temperature in 1 X TBST with 5% w/v nonfat dry milk, the blots were 
probed at 1:2500 dilution of the selected primary HuCAL PAR antibody 
and incubated overnight at 4°C. The nitrocellulose membranes were 
washed three times in 1 X TBST and probed with secondary Goat anti-
human IgG (Fab’)2 (HRP) (ab87422) at 1:5000 dilution. 
Immunostaining 
HeLa cell cultures and mouse cortical neurons were cultured on 
cover slips on 24-well cell culture plates (Falcon), (Nunc Thermo 
Scientific). Following 15 minutes of DMSO or MNNG treatment, cells were 
fixed in ice cold 4% paraformaldehyde (PFA) solution for 30 minutes. 
Subsequently, cover slips were washed three times in 1 X PBS and 




room temperature. Each of the antibody clones was diluted at 1:2500 in 
the blocking solution and probed to the cells overnight at 4°C. Cover slips 
were washed out for three times in 1 X PBS. Secondary antibodies Goat 
(Fab’)2 Anti-Human IgG H&L (FITC) (ab98524) was diluted 1:2000 in 1% 
Donkey serum, 0.1% Triton X-100 in PBS and administered to cover 
slips for 1 hour at room temperature. After washout , DAPI treatment 
was used for nuclear staining and cover slips were mounted to 
microscope glass slides using fluorescence immunomount media (Fisher 
Scientific) and visualized on a LSM510 (Carl Zeiss) microscope. 
Immunoprecipitation 
Neuronal cultures from a six-well plate (Nunc Thermo Scientific) 
were treated for 15 minutes in MNNG and collected in 0.5 mL Lysis 
buffer (PBS containing 1 mM EDTA, 1 mM EGTA, 0.5% SDS, 1% Nonidet 
P-40, 0.25 mM sodium orthovanadate, 0.25 mM PMSF, 2.5 µg/mL 
leupeptin, 2.5 µg/mL aprotinin) and incubated for 30 minutes at 4°C. 
Magnetic Ig binder Kappa beads (Millipore) were incubated with 
respective antibodies for 1 hour (10 ul slurry and 2.5 ug antibody) at 
room temperature with rotation. After the samples were washed three 
times with Tris-buffered saline containing 0.1% Tween 20 (TBST), PAR 
from cell lysates or radiolabelled PAR was added and incubated overnight 
at 4°C with rotation. Following  TBST washout and addition  of TBE 




20% TBE PAGE. The immunoblots were visualized in an ImageQuant 
LAS 4000 mini imaging analyzer (GE Healthcare) with enhanced 
chemiluminescence (Pierce). 
Direct Middle Cerebral Artery Occlusion (dMCAo) 
Mice were anesthetized with 1.5-2% isofluorane and maintained at 
normothermic temperature. To occlude the middle cerebral artery, a 7.0 
filament with a silicone tip was passed through the right internal carotid 
artery. 60 minutes occlusion was followed by a removal of the filament 
and reperfusion was performed. At 24 post reperfusion, the brain was 
harvested and sectioned into five coronal slabs to be stained with 
triphenyltetrazolium chloride (TTC). Infarct volume was measured on 
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